308 related articles for article (PubMed ID: 24857781)
1. Cytokine regulation by epidermal growth factor receptor inhibitors and epidermal growth factor receptor inhibitor associated skin toxicity in cancer patients.
Paul T; Schumann C; Rüdiger S; Boeck S; Heinemann V; Kächele V; Steffens M; Scholl C; Hichert V; Seufferlein T; Stingl JC
Eur J Cancer; 2014 Jul; 50(11):1855-63. PubMed ID: 24857781
[TBL] [Abstract][Full Text] [Related]
2. Epidermal EGFR controls cutaneous host defense and prevents inflammation.
Lichtenberger BM; Gerber PA; Holcmann M; Buhren BA; Amberg N; Smolle V; Schrumpf H; Boelke E; Ansari P; Mackenzie C; Wollenberg A; Kislat A; Fischer JW; Röck K; Harder J; Schröder JM; Homey B; Sibilia M
Sci Transl Med; 2013 Aug; 5(199):199ra111. PubMed ID: 23966300
[TBL] [Abstract][Full Text] [Related]
3. EGFR inhibitors switch keratinocytes from a proliferative to a differentiative phenotype affecting epidermal development and barrier function.
Joly-Tonetti N; Ondet T; Monshouwer M; Stamatas GN
BMC Cancer; 2021 Jan; 21(1):5. PubMed ID: 33402117
[TBL] [Abstract][Full Text] [Related]
4. EGFRI-associated health-related quality of life by severity of skin toxicity in metastatic colorectal cancer patients receiving epidermal growth factor receptor inhibitor target therapy.
Chiang TY; Hsu HC; Jane SW; Chen SC
Support Care Cancer; 2020 Oct; 28(10):4771-4779. PubMed ID: 31974771
[TBL] [Abstract][Full Text] [Related]
5. Arsenite and arsenate activate extracellular signal-regulated kinases 1/2 by an epidermal growth factor receptor-mediated pathway in normal human keratinocytes.
Tanaka-Kagawa T; Hanioka N; Yoshida H; Jinno H; Ando M
Br J Dermatol; 2003 Dec; 149(6):1116-27. PubMed ID: 14674888
[TBL] [Abstract][Full Text] [Related]
6. Ocular surface adverse events of systemic epidermal growth factor receptor inhibitors (EGFRi): A prospective trial.
Saint-Jean A; Reguart N; Eixarch A; Adán A; Castellà C; Sánchez-Dalmau B; Sainz-de-la-Maza M
J Fr Ophtalmol; 2018 Dec; 41(10):955-962. PubMed ID: 30473235
[TBL] [Abstract][Full Text] [Related]
7. Topical doxycycline foam 4% for prophylactic management of epidermal growth factor receptor inhibitor skin toxicity: an exploratory phase 2, randomized, double-blind clinical study.
Shacham Shmueli E; Geva R; Yarom N; Hubert A; Keynan R; Kedem TH; Eini M; Tamarkin D; Shirvan M
Support Care Cancer; 2019 Aug; 27(8):3027-3033. PubMed ID: 30607677
[TBL] [Abstract][Full Text] [Related]
8. Predictive blood plasma biomarkers for EGFR inhibitor-induced skin rash.
Hichert V; Scholl C; Steffens M; Paul T; Schumann C; Rüdiger S; Boeck S; Heinemann V; Kächele V; Seufferlein T; Stingl J
Oncotarget; 2017 May; 8(21):35193-35204. PubMed ID: 28456787
[TBL] [Abstract][Full Text] [Related]
9. Phenylbutyrate suppresses distinct skin reactions that are enhanced by blockade of epidermal growth factor receptor signaling.
Chung YL; Pui NN
J Dermatol Sci; 2011 Dec; 64(3):163-73. PubMed ID: 21924869
[TBL] [Abstract][Full Text] [Related]
10. IL-36γ drives skin toxicity induced by EGFR/MEK inhibition and commensal Cutibacterium acnes.
Satoh TK; Mellett M; Meier-Schiesser B; Fenini G; Otsuka A; Beer HD; Rordorf T; Maul JT; Hafner J; Navarini AA; Contassot E; French LE
J Clin Invest; 2020 Mar; 130(3):1417-1430. PubMed ID: 31805013
[TBL] [Abstract][Full Text] [Related]
11. Characterisation of the cutaneous pathology in non-small cell lung cancer (NSCLC) patients treated with the EGFR tyrosine kinase inhibitor erlotinib.
Guttman-Yassky E; Mita A; De Jonge M; Matthews L; McCarthy S; Iwata KK; Verweij J; Rowinsky EK; Krueger JG
Eur J Cancer; 2010 Jul; 46(11):2010-9. PubMed ID: 20621734
[TBL] [Abstract][Full Text] [Related]
12. Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Erlotinib Induces Dry Skin via Decreased in Aquaporin-3 Expression.
Ikarashi N; Kaneko M; Watanabe T; Kon R; Yoshino M; Yokoyama T; Tanaka R; Takayama N; Sakai H; Kamei J
Biomolecules; 2020 Apr; 10(4):. PubMed ID: 32260143
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of a Comprehensive Skin Toxicity Program for Patients Treated With Epidermal Growth Factor Receptor Inhibitors at a Cancer Treatment Center.
Yu Z; Dee EC; Bach DQ; Mostaghimi A; LeBoeuf NR
JAMA Dermatol; 2020 Oct; 156(10):1079-1085. PubMed ID: 32609305
[TBL] [Abstract][Full Text] [Related]
14. Epidermal growth factor receptor inhibitor-related skin toxicity: mechanisms, treatment, and its potential role as a predictive marker.
Bianchini D; Jayanth A; Chua YJ; Cunningham D
Clin Colorectal Cancer; 2008 Jan; 7(1):33-43. PubMed ID: 18279575
[TBL] [Abstract][Full Text] [Related]
15. The Epidermal Growth Factor Receptor Inhibitor-Related Skin Toxicity Index (EGFRISTI): a new tool for grading and managing skin adverse reactions to epidermal growth factor receptor inhibitors.
Lisi P; Bellini V; Bianchi L
Oncology; 2014; 87(5):311-9. PubMed ID: 25196815
[TBL] [Abstract][Full Text] [Related]
16. Epidermal growth factor receptor tyrosine kinase inhibitors induce CCL2 and CCL5 via reduction in IL-1R2 in keratinocytes.
Yamaki M; Sugiura K; Muro Y; Shimoyama Y; Tomita Y
Exp Dermatol; 2010 Aug; 19(8):730-5. PubMed ID: 20590818
[TBL] [Abstract][Full Text] [Related]
17. Acrolein induces activation of the epidermal growth factor receptor of human keratinocytes for cell death.
Takeuchi K; Kato M; Suzuki H; Akhand AA; Wu J; Hossain K; Miyata T; Matsumoto Y; Nimura Y; Nakashima I
J Cell Biochem; 2001; 81(4):679-88. PubMed ID: 11329622
[TBL] [Abstract][Full Text] [Related]
18. EGFR signaling suppresses type 1 cytokine-induced T-cell attracting chemokine secretion in head and neck cancer.
Ma W; Concha-Benavente F; Santegoets SJAM; Welters MJP; Ehsan I; Ferris RL; van der Burg SH
PLoS One; 2018; 13(9):e0203402. PubMed ID: 30192802
[TBL] [Abstract][Full Text] [Related]
19. Dosing to rash?--The role of erlotinib metabolic ratio from patient serum in the search of predictive biomarkers for EGFR inhibitor-mediated skin rash.
Steffens M; Paul T; Hichert V; Scholl C; von Mallek D; Stelzer C; Sörgel F; Reiser B; Schumann C; Rüdiger S; Boeck S; Heinemann V; Kächele V; Seufferlein T; Stingl J
Eur J Cancer; 2016 Mar; 55():131-9. PubMed ID: 26820683
[TBL] [Abstract][Full Text] [Related]
20. The Expression and Regulation of Interleukin-33 in Human Epidermal Keratinocytes: A New Mediator of Atopic Dermatitis and Its Possible Signaling Pathway.
Du HY; Fu HY; Li DN; Qiao Y; Wang QW; Liu W
J Interferon Cytokine Res; 2016 Sep; 36(9):552-62. PubMed ID: 27348082
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
